journal article·2014-07Open access

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

George R. Dakwar, Elisa Zagato, Joris Delanghe, Sabrina Hobel, Achim Aigner, Hannelore Denys, Kevin Braeckmans, Wim Ceelen, Stefaan C. De Smedt, Katrien Remaut

Acta Biomaterialia· Volume 10· Issue 7

Abstract

Intraperitoneal (IP) administration of nano-sized delivery vehicles containing small interfering RNA (siRNA) has recently gained attention as an alternative route for the efficient treatment of peritoneal carcinomatosis. The colloidal stability of nanomatter following IP administration has, however, not been thoroughly investigated yet. Here, enabled by advanced microscopy methods such as single particle tracking and fluorescence correlation spectroscopy, we follow the aggregation and cargo release of nano-scaled systems directly in peritoneal fluids from healthy mice and ascites fluid from a patient diagnosed with peritoneal carcinomatosis. The colloidal stability in the peritoneal fluids was systematically studied as a function of the charge (positive or negative) and poly(ethylene glycol) (PEG) degree of liposomes and polystyrene nanoparticles, and compared to human serum. Our data demonstrate strong aggregation of cationic and anionic nanoparticles in the peritoneal fluids, while only slight aggregation was observed for the PEGylated ones. PEGylated liposomes, however, lead to a fast and premature release of siRNA cargo in the peritoneal fluids. Based on our observations, we reflect on how to tailor improved delivery systems for IP therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Intraperitoneal and Appendiceal Malignancies · Hernia repair and management · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Ovarian cancer: etiology, risk factors, and epidemiology10.1097/GRF.0b013e31824b4611 ↗
2. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options10.3748/wjg.v18.i39.5489 ↗
3. Update in the management of ovarian and cervical carcinoma10.1007/s12094-007-0083-7 ↗
4. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer10.1200/JCO.2007.14.9898 ↗
5. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group10.1200/JCO.2006.09.2684 ↗
6. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer10.1056/NEJM199612263352603 ↗
7. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study10.1200/JCO.2003.02.153 ↗
8. Recent progress in the diagnosis and treatment of ovarian cancer10.3322/caac.20113 ↗
9. Peritoneal carcinomatosis of colorectal origin – incidence and current treatment strategies10.1097/01.sla.0000197702.46394.16 ↗
11. Intraperitoneal cisplatin and paclitaxel in ovarian cancer10.1056/NEJMoa052985 ↗
12. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study10.1200/JCO.2004.10.012 ↗
13. Pharmacokinetic rationale for peritoneal drug administration in treatment of ovarian cancer
14. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study10.1245/s10434-012-2264-z ↗
15. Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach?10.1155/2012/309417 ↗
16. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence10.1038/nrclinonc.2009.217 ↗
17. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study10.1245/s10434-011-1984-9 ↗
18. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels10.1016/j.jconrel.2011.11.025 ↗
19. Goldberg MS. siRNA delivery for the treatment of ovarian cancer, Methods [in press].
20. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance10.1016/j.nantod.2012.06.013 ↗
21. Drug delivery systems for intraperitoneal therapy10.1007/s11095-009-0031-z ↗
22. Intraperitoneal therapy for peritoneal cancer10.2217/fon.10.100 ↗
23. Nanocarriers for the targeted treatment of ovarian cancers10.1016/j.biomaterials.2012.10.055 ↗
24. Intraperitoneal delivery of nanoparticles for cancer gene therapy10.2217/fon.12.171 ↗
25. Poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer10.1016/j.jconrel.2012.12.005 ↗
26. Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application10.1016/S0168-3659(03)00131-7 ↗
27. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer10.1124/jpet.108.140095 ↗
28. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer10.1016/j.biomaterials.2012.10.077 ↗
29. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors10.1016/j.jconrel.2011.12.001 ↗
30. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model10.1007/s10637-010-9499-y ↗
31. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment10.1039/C1CS15233E ↗
32. Interactions between solubilized polymer molecules and blood components10.1016/j.jconrel.2012.02.005 ↗
33. Effects of the gene carrier polyethyleneimines on structure and function of blood components10.1016/j.biomaterials.2012.09.060 ↗
34. Protein corona significantly reduces active targeting yield10.1039/c3cc37307j ↗
35. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface10.1038/nnano.2012.237 ↗
36. Sizing nanomatter in biological fluids by fluorescence single particle tracking10.1021/nl103264u ↗
37. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles10.1016/j.nano.2008.08.001 ↗
38. A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum10.1016/j.jconrel.2007.10.024 ↗
39. An improved pyrogallol red molybdate method for determining total urinary protein10.1093/clinchem/35.11.2233 ↗
40. Automated serum protein electrophoresis by Capillarys (R)
41. Automated multicapillary electrophoresis for analysis of human serum proteins10.1373/clinchem.2003.017756 ↗
42. Determination of serum and blood densities10.1021/ac50045a052 ↗
43. Nuclear inclusion of nontargeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles10.1021/mp200120v ↗
44. Markedly elevated levels of vascular endothelial growth factor in malignant ascites10.1007/s10434-999-0373-0 ↗
45. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier10.1016/j.biomaterials.2012.11.058 ↗
46. Hemocompatibility of siRNA loaded dextran nanogels10.1016/j.biomaterials.2011.08.015 ↗
47. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids10.1016/S0006-3495(03)74798-5 ↗
48. Minireview: nanoparticles and the immune system10.1210/en.2009-1082 ↗
49. Cellular binding of nanoparticles in the presence of serum proteins10.1039/C0CC02618B ↗
50. Functional groups on polystyrene model nanoparticles: influence on protein adsorption10.1002/jbm.a.10371 ↗
51. Towards a better understanding of the dissociation behavior of liposome-oligonucleotide complexes in the cytosol of cells10.1016/j.jconrel.2004.12.017 ↗
52. Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy10.1016/j.jconrel.2005.09.048 ↗
53. Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick?10.1021/bi0519755 ↗
54. Can we better understand the intracellular behavior of DNA nanoparticles by fluorescence correlation spectroscopy?10.1016/j.jconrel.2007.04.008 ↗
55. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges10.1021/ar300048p ↗
56. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes10.1021/la803973p ↗
57. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum10.1002/jbm.a.30654 ↗
58. Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge10.1016/j.jconrel.2010.08.026 ↗
59. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel10.1007/s11095-007-9298-0 ↗